The global digital therapeutics market is projected to reach USD 17.7 billion by 2027 from USD 4.5 billion in 2022, at a CAGR of 31.6% during the forecast period. Increasing prevalence of chronic diseases, developments in digital therapeutics to curb growing healthcare costs and government initiatives to support the digital therapeutics are driving the market growth.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=51646724

Digital therapeutics are evidence-based therapeutic interventions delivered through software applications, leveraging the power of smartphones, wearables, and other digital platforms. These solutions aim to prevent, manage, or treat medical conditions in a more accessible and patient-centric manner.

The DTx market has been growing rapidly in recent years due to advancements in technology, increased adoption of smartphones and wearables, and a growing demand for more accessible and personalized healthcare solutions. Some key features and benefits of digital therapeutics include:

Accessibility: DTx solutions can be accessed remotely through smartphones, tablets, or computers, making healthcare more convenient and accessible for patients, especially those in remote areas.

Personalization: Digital therapeutics can be tailored to individual patient needs, taking into account their medical history, preferences, and progress over time.

Cost-effectiveness: Digital therapeutics can potentially reduce healthcare costs by offering scalable solutions that require fewer physical resources compared to traditional treatments.Real-time monitoring: Many DTx applications incorporate data collection and analysis, allowing healthcare providers to monitor patient progress and adjust treatments accordingly.

Patient engagement: Gamification and interactive elements in DTx apps can enhance patient engagement, adherence, and motivation.

Clinical evidence: Most reputable digital therapeutics are backed by clinical studies to demonstrate their safety and effectiveness.

Access Complete Report @ https://www.globenewswire.com/en/news-release/2023/03/15/2627647/0/en/Digital-Therapeutics-DTx-Market-is-Expected-to-Reach-17-7-billion-MarketsandMarkets.html

North America commanded the largest share of the digital therapeutics market.

North America held the largest share of the DTx Market, followed by Europe. The market in North America is also expected to grow at the highest CAGR of 32.2%. Factors such as the influx of new start-ups, increasing investments in digital therapeutics, improvements in the reimbursement structure for digital therapeutics, and government initiatives to support technological advancements drive market growth in this region.

Key Market Players

Prominent players in the digital therapeutics market include Noom (US), Livongo Health (US), Omada Health (US), WellDoc (US), Pear Therapeutics (US), Proteus Digital Health (US), Propeller Health (US), Akili Interactive Labs (US), Better Therapeutics (US), Happify (US), Kaia Health (Germany), Mango Health (US), Click Therapeutics (US), Canary Health (US), Wellthy Therapeutics (India), Cognoa (US), CogniFit (US), Ayogo Health (Canada), Mindstrong Health (US), 2Morrow (US), and Ginger (US).

Noom, Inc. (US) is among the world leaders digital therapeutics market in providing high-quality solutions for weight management, diabetes prevention, and stress reduction. Noom has been awarded multiple grants from the National Institutes of Health and provided the first mobile application recognized by the US CDC as a certified diabetes prevention program.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=51646724

About MarketsandMarkets™ 

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441

Email: sales@marketsandmarkets.com

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/digital-therapeutics-market.asp